GENE ONLINE|News &
Opinion
Blog

Bladder Cancer
Trials & Approvals Bladder CancerFDA Approval
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
R&D Gene Mutation
An Enzyme that Defends Against Viruses Could Double Cancer Mutations
2023-01-06
Regulatory FDA
FDA Rejects Sesen Bio’s Bladder Cancer Drug Application, Asks Additional Data
2021-08-16
Trials & Approvals Bladder Cancer
AstraZeneca Voluntarily Withdraws Checkpoint Inhibitor Approved for Bladder Cancer Indication
2021-02-25
Trials & Approvals Bladder Cancer
Bavencio Bags FDA Approval as First-line Maintenance Treatment for Urothelial Carcinoma
2020-07-05
R&D
ASCO 2020: Maintenance Therapy with Avelumab Post-Chemo Improves Overall Survival of Bladder Cancer Patients
2020-05-29
Interviews Precision Medicine
How Can Data Science Help Fighting Against Prostate Cancer? Interview with Genomic Scientist Dr. Mohamed Alshalalfa
2019-05-30
LATEST
Sanofi and Regeneron’s Dupixent Approved as First-in-World Treatment For Uncontrolled COPD
2024-07-04
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
2024-07-04
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
2024-07-04
BIO Asia–Taiwan 2024 Set to Showcase Global Biotech Industry Talent on July 24th
2024-07-03
Novo Nordisk’s CLARION-CKD Trial Shut Down After Unsuccessful Results Causing Impairment Loss
2024-07-03
Tanvex BioPharma Secures Asia’s First FDA Approval for Filgrastim Biosimilar, Seizing a $403 Million Market
2024-07-03
Ginkgo Job Cuts Expected to Affect at Least 35% of Workforce, Eliminating Over 400 Jobs
2024-07-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top